MCID: TRP002
MIFTS: 50

Tropical Spastic Paraparesis

Categories: Infectious diseases, Neuronal diseases

Aliases & Classifications for Tropical Spastic Paraparesis

MalaCards integrated aliases for Tropical Spastic Paraparesis:

Name: Tropical Spastic Paraparesis 12 74 53 15 17 71
Tropical Spastic Paraplegia 12 32
Paraparesis, Tropical Spastic 43
Paraparesis Tropical Spastic 54
Htlv-Associated Myelopathy 12
Tropical Spastic Paralysis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:321
MeSH 43 D015493
SNOMED-CT 67 714279000
ICD10 32 G04.1
UMLS 71 C0030481

Summaries for Tropical Spastic Paraparesis

NINDS : 53 For several decades the term “tropical spastic paraparesis” (TSP) has been used to describe a chronic and progressive disease of the nervous system that affects adults living in equatorial areas of the world and causes progressive weakness, stiff muscles, muscle spasms, sensory disturbance, and sphincter dysfunction. The cause of TSP was obscure until the mid-1980s, when an important association was established between the human retrovirus — human T-cell lymphotrophic virus type 1 (also known as HTLV-1) — and TSP. TSP is now called HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP. The HTLV-1 retrovirus is thought to cause at least 80 percent of the cases of HAM/TSP by impairing the immune system. In addition to neurological symptoms of weakness and muscle stiffness or spasms, in rare cases individuals with HAM/TSP also exhibit uveitis (inflammation of the uveal tract of the eye), arthritis (inflammation of one or more joints), pulmonary lymphocytic alveolitis (inflammation of the lung), polymyositis (an inflammatory muscle disease), keratoconjunctivitis sicca (persistent dryness of the cornea and conjunctiva), and infectious dermatitis (inflammation of the skin). The other serious complication of HTLV-1 infection is the development of adult T-cell leukemia or lymphoma. Nervous system and blood-related complications occur only in a very small proportion of infected individuals, while most remain largely without symptoms throughout their lives. The HTLV-1 virus is transmitted person-to-person via infected cells: breast-feeding by mothers who are seropositive (in other words, have high levels of virus antibodies in their blood), sharing infected needles during intravenous drug use, or having sexual relations with a seropositive partner. Less than 2 percent of HTLV-1 seropositive carriers will become HAM/TSP patients.

MalaCards based summary : Tropical Spastic Paraparesis, also known as tropical spastic paraplegia, is related to t-cell adult acute lymphocytic leukemia and myelitis. An important gene associated with Tropical Spastic Paraparesis is CNTN2 (Contactin 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pentoxifylline and Zidovudine have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and breast, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A viral infectious disease that results in inflammation located in spinal cord, has material basis in Human T-lymphotropic virus 1, which is transmitted by sexual contact, and transmitted by breast feeding. The infection has symptom spastic weakness of both legs, has symptom muscle stiffness, has symptom sensory disturbance, and has symptom spasms.

Wikipedia : 74 Tropical spastic paraparesis (TSP), is a medical condition that causes weakness, muscle spasms, and... more...

Related Diseases for Tropical Spastic Paraparesis

Diseases related to Tropical Spastic Paraparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 445)
# Related Disease Score Top Affiliating Genes
1 t-cell adult acute lymphocytic leukemia 31.6 IL2 FOXP3 CNTN2
2 myelitis 31.2 MMP9 IL6 IL10
3 syphilis 31.2 IL6 IFNG B2M
4 adult t-cell leukemia 31.1 NFKBIA IL2RA IL2 IL15 FOXP3 CNTN2
5 thyroiditis 30.9 IL6 IL2 IL10 FOXP3
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.8 IL10 IFNG FOXP3
7 herpes zoster 30.8 IL2 IL10 IFNG
8 allergic encephalomyelitis 30.7 CCL5 CCL3
9 dermatitis 30.7 IL6 IL2RB IL2 IL10 IFNG CXCR3
10 measles 30.7 IL6 IL2RA IL2 IFNG CCL5
11 uveitis 30.7 IL6 IL2RA IL2 IL10 IFNG CXCR3
12 purpura 30.7 IL6 IL10 IFNG
13 mumps 30.7 IL6 IL2RA IL2 IL10 IFNG
14 peripheral nervous system disease 30.6 IL6 IL2 IL10 IFNG B2M
15 folliculitis 30.6 IL2RA IFNG CCL5
16 candidiasis 30.6 IL6 IL2 IL10 IFNG
17 chickenpox 30.6 IL6 IL2 IL10 IFNG
18 nervous system disease 30.6 MMP9 IL6 IFNG CXCR3
19 subacute sclerosing panencephalitis 30.6 IL6 IL2 IL10 IFNG
20 graft-versus-host disease 30.6 IL6 IL2 IL10 IFNG
21 spinal cord disease 30.6 IL6 IL2 IL10 CNTN2
22 toxoplasmosis 30.6 IL6 IL10 IFNG CCL3
23 t-cell lymphoblastic leukemia/lymphoma 30.4 NFKBIA JUN IL2RB IL2RA IL2 FOXP3
24 central nervous system disease 30.4 MMP9 IL6 IFNG CXCR3
25 cystitis 30.4 JUN IL6 IL2 CXCR3
26 schistosomiasis 30.3 IL2 IL10 IFNG CCL5 CCL3
27 cytomegalovirus infection 30.2 IL6 CCL5 CCL3 B2M
28 rubella 30.1 TRIM5 IL6 IL2RA IL2 IL10 IFNG
29 lichen planus 30.0 IL6 IL2 IL10 IFNG CXCR3 CCL5
30 alopecia areata 29.9 IL6 IL2RA IL2 IL10 IFNG FOXP3
31 skin disease 29.9 IL6 IL2 IL10 IFNG CXCR3 B2M
32 cutaneous t cell lymphoma 29.8 IL2RB IL2RA IL2 IL15 IFNG CXCR3
33 osteoporosis 29.7 MMP9 JUN IL6 IL2 IL10 IFNG
34 mycosis fungoides 29.5 IL2RB IL2RA IL2 IL15 IFNG FOXP3
35 acquired immunodeficiency syndrome 29.5 IL6 IL2RB IL2RA IL2 IL15 IL10
36 neuroblastoma 29.5 NFKBIA MMP9 JUN IL6 IL2 IFNG
37 psoriasis 29.2 IL6 IL2RA IL2 IL15 IL10 IFNG
38 lung disease 29.0 MMP9 IL6 IL15 IL10 IFNG CXCR3
39 autoimmune disease 28.8 TNFRSF18 MMP9 IL6 IL2RA IL2 IL15
40 human immunodeficiency virus type 1 28.7 TRIM5 NFKBIA IL2 IL10 IFNG ERVW-1
41 systemic lupus erythematosus 27.9 MMP9 IL6 IL2RB IL2RA IL2 IL15
42 multiple sclerosis 27.7 MMP9 IL6 IL2RB IL2RA IL2 IL15
43 htlv-1 associated myelopathy/tropical spastic paraparesis 13.0
44 myelopathy, htlv-1-associated 12.7
45 retrovirus-associated myelopathy 12.0
46 human t-cell leukemia virus type 1 11.9
47 spastic paraparesis 11.4
48 leukemia, t-cell, chronic 11.0
49 spasticity 10.7
50 fixed drug eruption 10.6 IL2 IFNG

Graphical network of the top 20 diseases related to Tropical Spastic Paraparesis:



Diseases related to Tropical Spastic Paraparesis

Symptoms & Phenotypes for Tropical Spastic Paraparesis

MGI Mouse Phenotypes related to Tropical Spastic Paraparesis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 B2M CCL5 CXCR3 FOXP3 IFNG IFNL3
2 immune system MP:0005387 10.27 B2M CCL5 CXCR3 FOXP3 IFNG IFNL3
3 cardiovascular system MP:0005385 10.25 B2M CXCR3 FOXP3 IFNG IL10 IL15
4 cellular MP:0005384 10.24 B2M CXCR3 FOXP3 IFNG IL10 IL2
5 growth/size/body region MP:0005378 10.21 B2M FOXP3 IFNG IL10 IL15 IL2
6 endocrine/exocrine gland MP:0005379 10.2 B2M FOXP3 IFNG IL10 IL15 IL2
7 digestive/alimentary MP:0005381 10.08 B2M FOXP3 IFNG IL10 IL2 IL2RA
8 integument MP:0010771 9.97 B2M FOXP3 IFNG IL10 IL2RB IL6
9 mortality/aging MP:0010768 9.97 B2M CXCR3 FOXP3 IFNG IL10 IL15
10 liver/biliary system MP:0005370 9.86 B2M FOXP3 IFNG IL10 IL2 IL2RB
11 neoplasm MP:0002006 9.5 B2M CXCR3 IFNG IL10 IL2 IL6
12 respiratory system MP:0005388 9.28 CXCR3 FOXP3 IFNG IL10 IL2 IL2RA

Drugs & Therapeutics for Tropical Spastic Paraparesis

Drugs for Tropical Spastic Paraparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
2
Zidovudine Approved Phase 2, Phase 3 30516-87-1 35370
3
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
4
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
5
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
6
Mogamulizumab Approved, Investigational Phase 3 1159266-37-1
7 Phosphodiesterase Inhibitors Phase 3
8 Antioxidants Phase 3
9 Platelet Aggregation Inhibitors Phase 3
10 Vasodilator Agents Phase 3
11 Protective Agents Phase 3
12 Radiation-Protective Agents Phase 3
13 Anti-HIV Agents Phase 2, Phase 3
14 Reverse Transcriptase Inhibitors Phase 2, Phase 3
15 Anti-Infective Agents Phase 2, Phase 3
16 Antiviral Agents Phase 2, Phase 3
17 Anti-Retroviral Agents Phase 2, Phase 3
18 Antimetabolites Phase 2, Phase 3
19 Dermatologic Agents Phase 2, Phase 3
20 Antirheumatic Agents Phase 2, Phase 3
21 Immunologic Factors Phase 2, Phase 3
22 Cyclosporins Phase 2, Phase 3
23 Immunosuppressive Agents Phase 2, Phase 3
24 Antifungal Agents Phase 2, Phase 3
25 Calcineurin Inhibitors Phase 2, Phase 3
26
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
27
Infliximab Approved Phase 2 170277-31-3
28 Interferon-beta Phase 2
29 Adjuvants, Immunologic Phase 2
30 interferons Phase 2
31 Janus Kinase Inhibitors Phase 2
32 Gastrointestinal Agents Phase 2
33 Immunoglobulins Phase 1
34 Antibodies Phase 1
35 Antibodies, Monoclonal Phase 1
36
Valproic acid Approved, Investigational 99-66-1 3121
37 Integrase Inhibitors Early Phase 1
38 HIV Integrase Inhibitors Early Phase 1
39 Raltegravir Potassium Early Phase 1
40 Neurotransmitter Agents
41 Psychotropic Drugs
42 Anticonvulsants

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
2 Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3 Tamibarotene
3 Effectiveness of Pentoxifylline in Attenuating Neurological Disease Associated With HTLV-1 and Negative Modulator of Pathological Immune Response. Completed NCT01472263 Phase 3 Pentoxifylline;Placebo
4 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3 Zidovudine/lamivudine;Placebos
5 The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP Completed NCT00773292 Phase 2, Phase 3 ciclosporin
6 A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) Active, not recruiting NCT03191526 Phase 3 KW-0761 0.3 mg/kg IV;Placebo (saline)
7 Combined Virological and Immunological Evaluation of Treatment of Patients With Early HTLV-1-Associated Myelopathy With Recombinant Human Interferon Beta-1a Completed NCT00001785 Phase 2 Recombinant human interferon beta-1a
8 Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL) Recruiting NCT01712659 Phase 2 Ruxolitinib;ruxolitinib
9 An Open, Non-randomised Pilot Study of Anti-TNF-alpha Therapy in Early or Progressing HAM/TSP Terminated NCT00823641 Phase 2 Infliximab
10 Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action Completed NCT00076843 Phase 1 Hu MiK-Beta-1
11 Evaluation of the MP Diagnostics HTLV Blot 2.4 Unknown status NCT01467024
12 Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study Completed NCT02655471 Early Phase 1 "Raltegravir" and "Zidovudine"
13 A Study of Familial and Genetic Aspects of Adult T-Cell Leukemia/Lymphoma, Tropical Spastic Paraparesis and Infective Dermatitis in Jamaica Completed NCT00340821
14 Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1 Completed NCT01651819
15 MRI Investigation Of The CNS In HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00034723
16 Combined Clinical, Immunological and Virological Assessment of Patients With Multiple Sclerosis (MS) Completed NCT00001156
17 Evaluation of the MP Diagnostics HTLV Blot 2.4 Completed NCT03146013
18 Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1 Completed NCT01754311
19 Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Completed NCT01867320 Early Phase 1 Raltegravir
20 Retrovirus Epidemiology Donor Study I (REDS I) Completed NCT00005278
21 Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP) Recruiting NCT00001778
22 Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1 Recruiting NCT03829709
23 Open Label Study of the Clinical and Laboratory Effects of Valproic Acid In HAM/TSP Terminated NCT00519181 Valproic Acid

Search NIH Clinical Center for Tropical Spastic Paraparesis

Cochrane evidence based reviews: paraparesis, tropical spastic

Genetic Tests for Tropical Spastic Paraparesis

Anatomical Context for Tropical Spastic Paraparesis

MalaCards organs/tissues related to Tropical Spastic Paraparesis:

40
T Cells, Spinal Cord, Breast, Eye, Lung, Skin, Brain

Publications for Tropical Spastic Paraparesis

Articles related to Tropical Spastic Paraparesis:

(show top 50) (show all 1566)
# Title Authors PMID Year
1
Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-I-associated myelopathy. 61 54
18639344 2008
2
High production of RANTES and MIP-1alpha in the tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). 54 61
17588676 2007
3
Blockade of IL-2 receptor suppresses HTLV-I and IFN-gamma expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 54 61
17409595 2007
4
Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. 54 61
16879249 2006
5
Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. 54 61
16652169 2006
6
Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia. 54 61
16387851 2006
7
Involvement of p38 MAPK signaling pathway in IFN-gamma and HTLV-I expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 61 54
15652420 2005
8
Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). 54 61
15465610 2004
9
TIMPs and MMPs expression in CSF from patients with TSP/HAM. 54 61
12697269 2003
10
Detection of myelin basic protein in cerebrospinal fluid and serum from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 54 61
12564844 2002
11
Detection of myelin basic protein in cerebrospinal fluid. 61 54
12465458 2002
12
High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. 54 61
11964301 2002
13
Up-regulation of interleukin-12 receptor expression in peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. 54 61
11959151 2002
14
IRF-4 activities in HTLV-I-induced T cell leukemogenesis. 54 61
11846984 2002
15
IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. 54 61
11717409 2001
16
How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis? 54 61
11080816 2000
17
[Increased activity of metalloproteinases and their inhibitors in cerebrospinal fluid of patients with tropical spastic paraparesis]. 61 54
11016056 2000
18
Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. 61 54
10491011 1999
19
Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients. 54 61
10430056 1999
20
HTLV-I-infected T cells evade the antiproliferative action of IFN-beta. 61 54
10329542 1999
21
Gelatinase activity of matrix metalloproteinases in the cerebrospinal fluid of various patient populations. 61 54
10604277 1999
22
Predominant expression of Fas ligand mRNA in CD8+ T lymphocytes in patients with HTLV-1 associated myelopathy. 61 54
9817448 1998
23
Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. 54 61
9633766 1998
24
Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. 54 61
9482906 1998
25
Costimulation of cytokine gene expression in T cells by the human T leukemia/lymphotropic virus type 1 trans activator Tax. 54 61
8648737 1996
26
Sequence analysis of human T cell lymphotropic virus type I (HTLV-I) Env genes amplified from central nervous system tissues of patients with HTLV-I-associated myelopathy or leukemia. 61 54
8778566 1995
27
Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. 61 54
8301322 1994
28
Virion-associated trans-regulatory protein of human T-cell leukemia virus type I. 54 61
1540409 1992
29
Failure to demonstrate human T cell lymphotropic virus type I in multiple sclerosis patients. 54 61
2189023 1990
30
Molecular targeting of PD-1 signaling pathway as a novel therapeutic approach in HTLV-1 infection. 61
32283259 2020
31
Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient. 61
31930455 2020
32
Tropical spastic paraparesis in autochthon patient. 61
31784111 2020
33
Early-Onset HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. 61
32517313 2020
34
Phylogenetic and phylodynamic study of Human T-cell lymphotropic virus Type 1 (HTLV-1) in Iran. 61
32561293 2020
35
Frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in Japanese macaques. 61
32576215 2020
36
Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis. 61
32393644 2020
37
Signs, meanings and practices of people living with human t-cell lymphotropic virus type 1 or tropical spastic myelopathy. 61
32367401 2020
38
Neurologic, clinical, and immunologic features in a cohort of HTLV-1 carriers with high proviral loads. 61
32385802 2020
39
Expression of TSLC1 in patients with HAM/TSP. 61
32285300 2020
40
Complete genome sequence of human T-cell lymphotropic type 1 from patients with different clinical profiles, including infective dermatitis. 61
31883457 2020
41
Clinicopathological aspects and proviral load of adulthood infective dermatitis associated with HTLV-1: Comparison between juvenile and adulthood forms. 61
32330142 2020
42
Acupuncture in the treatment of HTLV-I-associated myelopathy / tropical spastic Paraparesis. 61
32350814 2020
43
The IL-18, IL-12, and IFN-γ expression in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients, HTLV-1 carriers, and healthy subjects. 61
32270468 2020
44
Effective Treatment with Tocilizumab in a Rheumatoid Arthritis Patient Complicated with Human T-cell Leukemia Virus Type 1-associated Myelopathy: A Case Report. 61
32321893 2020
45
First Description of Seronegative HTLV-1 Carriers in Argentina. 61
32043459 2020
46
Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids. 61
31662348 2020
47
Infective dermatitis: A purely cutaneous manifestation of HTLV-1 infection. 61
31010607 2020
48
The effect of home exercise on the posture and mobility of people with HAM/TSP: a randomized clinical trial. 61
32236329 2020
49
Enigma of tropical spastic paraplegia. 61
32415001 2020
50
Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma. 61
32054656 2020

Variations for Tropical Spastic Paraparesis

Expression for Tropical Spastic Paraparesis

Search GEO for disease gene expression data for Tropical Spastic Paraparesis.

Pathways for Tropical Spastic Paraparesis

Pathways related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 TRIM5 TNFRSF18 NFKBIA MMP9 JUN IL6
2
Show member pathways
13.9 TNFRSF18 NFKBIA JUN IL6 IL2RB IL2RA
3
Show member pathways
13.73 TNFRSF18 NFKBIA JUN IL6 IL2RB IL2RA
4
Show member pathways
13.63 TNFRSF18 NFKBIA JUN IL6 IL2RB IL2RA
5
Show member pathways
13.5 TNFRSF18 IL6 IL2RB IL2RA IL2 IL15
6
Show member pathways
13.36 TNFRSF18 NFKBIA JUN IL6 IL2RB IL2RA
7
Show member pathways
13.16 NFKBIA MMP9 JUN IL6 IL2 IL10
8
Show member pathways
13.11 TRIM5 TNFRSF18 MMP9 IL6 IL2RB IL2RA
9
Show member pathways
13.04 TRIM5 NFKBIA JUN IL6 CCL5 CCL3
10
Show member pathways
12.97 IL6 IL2RA IL2 IL15 IL10 IFNG
11 12.96 NFKBIA MMP9 JUN IL6 IL2RB IL2RA
12
Show member pathways
12.93 NFKBIA JUN IL6 IL2RB IL2RA IL2
13
Show member pathways
12.88 NFKBIA JUN IL6 IL2RB IL2RA IL2
14 12.84 NFKBIA IL6 IFNG CCL5 B2M
15
Show member pathways
12.74 NFKBIA JUN IL2RA IL2 IL10 IFNG
16
Show member pathways
12.71 NFKBIA JUN IL6 IL2 IL10 IFNG
17
Show member pathways
12.66 NFKBIA IL6 IL2 IL10 IFNG
18
Show member pathways
12.62 NFKBIA JUN IL6 IL2RB IL2RA IL2
19
Show member pathways
12.59 IL6 IL2RB IL2RA IL2 IL15 IL10
20 12.54 TNFRSF18 NFKBIA IL2RB IL2RA IL2 IL10
21
Show member pathways
12.49 NFKBIA JUN IL2RB IL2RA IL2
22
Show member pathways
12.48 NFKBIA JUN IL2RA IL2
23
Show member pathways
12.44 NFKBIA MMP9 JUN IL6 IFNG
24 12.44 NFKBIA JUN IL6 IL2RB IL2RA IL2
25
Show member pathways
12.39 IL6 IL2RB IL2RA IL2 IL10 CXCR3
26
Show member pathways
12.38 IL6 IL2 IFNG CCL5
27
Show member pathways
12.37 IL6 IL2RA IL2 IL15 IL10 IFNG
28
Show member pathways
12.35 NFKBIA JUN IL6 IFNG
29
Show member pathways
12.32 NFKBIA JUN IL10 IFNG
30
Show member pathways
12.32 NFKBIA JUN IL6 IL2 IL10
31 12.3 NFKBIA JUN IL6 CCL5
32
Show member pathways
12.25 NFKBIA JUN IL6 IFNG
33
Show member pathways
12.23 IL2RB IL2RA IL2 IL15
34
Show member pathways
12.19 JUN IL2RB IL2RA IL2 IFNG
35 12.14 NFKBIA JUN IL6 IL2 IL10
36 12.13 NFKBIA MMP9 JUN IL6 IL15 CCL5
37
Show member pathways
12.11 NFKBIA JUN IL2RA IL2
38 12.1 MMP9 IL6 IL2 IFNG
39 12.09 IL6 IL2RB IL2RA IL2 IL15 IL10
40
Show member pathways
12.07 JUN IL6 IL2 IL10 IFNG
41 12.04 JUN IL6 IFNG CCL3
42 12.02 JUN IL6 IL15 IFNG CCL5 CCL3
43 11.92 JUN IL6 IL2 IFNG
44
Show member pathways
11.91 JUN IL2RA IL2 IFNG FOXP3
45
Show member pathways
11.91 NFKBIA JUN IL2RB IL2RA IL2 IFNG
46 11.87 IL6 IL2 IL10 IFNG
47
Show member pathways
11.84 NFKBIA JUN IL2
48
Show member pathways
11.82 IL2RB IL2RA IL2 FOXP3
49 11.8 JUN IL6 IL10
50 11.8 NFKBIA MMP9 JUN IL6

GO Terms for Tropical Spastic Paraparesis

Cellular components related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.73 IL2RB IL2RA IL15 CXCR3 CNTN2 B2M
2 external side of plasma membrane GO:0009897 9.72 TNFRSF18 IL2RB IL2RA CXCR3 B2M
3 extracellular region GO:0005576 9.7 TNFRSF18 MMP9 IL6 IL2 IL15 IL10
4 extracellular space GO:0005615 9.32 MMP9 IL6 IL2 IL15 IL10 IFNL3
5 interleukin-2 receptor complex GO:0005893 9.16 IL2RB IL2RA

Biological processes related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.97 IL2 IL15 CCL5 CCL3
2 inflammatory response GO:0006954 9.97 IL6 IL2RA IL15 CXCR3 CCL5 CCL3
3 negative regulation of apoptotic process GO:0043066 9.97 TNFRSF18 NFKBIA MMP9 JUN IL6 IL2RB
4 defense response to virus GO:0051607 9.93 TRIM5 IL6 IFNL3 IFNG
5 MAPK cascade GO:0000165 9.92 IL2RB IL2RA IL2 CCL5 CCL3
6 negative regulation of inflammatory response GO:0050728 9.87 IL2RA IL2 IL10 FOXP3
7 cell chemotaxis GO:0060326 9.85 CXCR3 CCL5 CCL3
8 chemokine-mediated signaling pathway GO:0070098 9.82 CXCR3 CCL5 CCL3
9 interferon-gamma-mediated signaling pathway GO:0060333 9.82 TRIM5 IFNG B2M
10 positive regulation of smooth muscle cell proliferation GO:0048661 9.8 JUN IL6 CCL5
11 positive regulation of inflammatory response GO:0050729 9.8 NFKBIA IL2 IL15 IFNG CCL3
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.77 MMP9 JUN IL10
13 positive regulation of phagocytosis GO:0050766 9.77 IL2RB IL15 IFNG
14 monocyte chemotaxis GO:0002548 9.76 IL6 CCL5 CCL3
15 negative regulation of T cell proliferation GO:0042130 9.75 IL2RA IL10 FOXP3
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 NFKBIA CCL5 CCL3
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNFRSF18 IL6 IL2 IL15 IFNG CCL5
18 positive regulation of T cell proliferation GO:0042102 9.72 IL6 IL2RA IL2 IL15 CCL5
19 positive regulation of JAK-STAT cascade GO:0046427 9.71 IL6 IL10 CCL5
20 macrophage differentiation GO:0030225 9.69 MMP9 IL15 IFNG
21 positive regulation of immunoglobulin secretion GO:0051024 9.68 IL6 IL2
22 neutrophil activation GO:0042119 9.67 IL15 CCL5
23 T cell chemotaxis GO:0010818 9.67 CXCR3 CCL3
24 regulation of neuroinflammatory response GO:0150077 9.66 MMP9 IL6
25 response to molecule of bacterial origin GO:0002237 9.66 IL10 B2M
26 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL10 IFNG
27 negative regulation of lipid storage GO:0010888 9.65 NFKBIA IL6
28 negative regulation by host of viral transcription GO:0043922 9.65 JUN CCL5 CCL3
29 immune response GO:0006955 9.65 IL6 IL2RA IL2 IL15 IL10 IFNG
30 negative regulation of T-helper 17 cell differentiation GO:2000320 9.64 IL2 FOXP3
31 cytoplasmic sequestering of NF-kappaB GO:0007253 9.63 NFKBIA IL10
32 interleukin-2-mediated signaling pathway GO:0038110 9.63 IL2RB IL2RA IL2
33 positive regulation of receptor binding GO:1900122 9.62 MMP9 B2M
34 positive regulation of natural killer cell chemotaxis GO:2000503 9.61 CCL5 CCL3
35 positive regulation of tissue remodeling GO:0034105 9.61 IL2 IL15
36 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2RA IL2 FOXP3
37 regulation of T cell homeostatic proliferation GO:0046013 9.55 IL2RA IL2
38 regulation of regulatory T cell differentiation GO:0045589 9.55 TNFRSF18 IL2RA IL2 IFNG FOXP3
39 cytokine-mediated signaling pathway GO:0019221 9.28 MMP9 IL6 IL2RB IL2RA IL2 IL10

Molecular functions related to Tropical Spastic Paraparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TRIM5 TNFRSF18 NFKBIA MMP9 JUN IL6
2 identical protein binding GO:0042802 9.65 TRIM5 NFKBIA MMP9 JUN FOXP3 CXCR3
3 CCR5 chemokine receptor binding GO:0031730 9.43 CCL5 CCL3
4 phospholipase activator activity GO:0016004 9.4 CCL5 CCL3
5 CCR1 chemokine receptor binding GO:0031726 9.32 CCL5 CCL3
6 interleukin-2 binding GO:0019976 9.26 IL2RB IL2RA
7 cytokine activity GO:0005125 9.23 IL6 IL2 IL15 IL10 IFNL3 IFNG
8 interleukin-2 receptor activity GO:0004911 9.16 IL2RB IL2RA

Sources for Tropical Spastic Paraparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....